AEON Biopharma, Inc.

Equities

AEON

US00791X1000

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.99 ^USD	-21.30%		-15.47%	-44.58%

Apr. 12	AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	CI
Apr. 01	Sector Update: Health Care Stocks Slide Late Afternoon	MT

AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 29, 2024 at 03:49 pm EDT

AEON Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 36.63 million compared to USD 52.56 million a year ago.

Latest news about AEON Biopharma, Inc.

AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Apr. 11	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
AEON Biopharma Shares Tumble on Wider Q4 Loss	Apr. 01	MT
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	Mar. 19	CI
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	Mar. 18	CI
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 19	MT
AEON Biopharma Says Cervical Dystonia Treatment Well-Tolerated in Phase 2 Study	Jan. 19	MT
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024	Jan. 18	CI
AEON Biopharma, Inc. Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	Dec. 12	CI
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
AEON Biopharma Reports Mid-Stage Migraine Trial Misses Statistical Significance	23-10-19	MT
AEON Biopharma, Inc. Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	23-10-19	CI
AEON Biopharma, Inc.(NYSEAM:AEON) added to S&P TMI Index	23-09-18	CI
Top Premarket Gainers	23-08-30	MT
AEON Biopharma, Inc. Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia At the International Parkinson and Movement Disorders Society Congress®	23-08-29	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	23-08-24	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	23-08-24	MT
Sector Update: Health Care	23-08-24	MT
AEON Biopharma Gets Notice of Allowance for Soon-to-Issue US Patent Covering Its Migraine Treatment Candidate	23-08-24	MT
HC Wainwright Starts AEON Biopharma at Buy With $18 Price Target	23-08-18	MT

Chart AEON Biopharma, Inc.

Duration

Period

More charts

Company Profile

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.07 USD

Average target price

18 USD

Spread / Average Target

+255.03%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AEON BIOPHARMA, INC.	-44.58%	192M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs